Adverse drug reaction
Adverse drug reaction | |
---|---|
A rash due to a drug reaction |
An adverse drug reaction (ADR) is a harmful, unintended result caused by taking medication.[1]: 1.1 Adverse Drug Reaction (ADR) [2] ADRs may occur following a single dose or prolonged administration of a drug or may result from the combination of two or more drugs. The meaning of this term differs from the term "side effect" because side effects can be beneficial as well as detrimental.[3] The study of ADRs is the concern of the field known as pharmacovigilance.[3] An adverse event (AE) refers to any unexpected and inappropriate occurrence at the time a drug is used, whether or not the event is associated with the administration of the drug.[1]: 1.2 Adverse Event (AE) An ADR is a special type of AE in which a causative relationship can be shown.[3] ADRs are only one type of medication-related harm. Another type of medication-related harm type includes not taking prescribed medications, known as non-adherence.[4] Non-adherence to medications can lead to death and other negative outcomes.[4] Adverse drug reactions require the use of a medication.[3]
Classification
Traditional
- Type A: augmented pharmacological effects, which are dose-dependent and predictable[5]
- Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant intracranial bleeding from warfarin). Such reactions are usually due to inappropriate dosage, especially when drug elimination is impaired. The term side effects may be applied to minor type A reactions.[6]
- Type B: Type B reactions are not dose-dependent and are not predictable, and so may be called idiosyncratic.[5] These reactions can be due to particular elements within the person or the environment.[7]
Types A and B were proposed in the 1970s,[8] and the other types were proposed subsequently when the first two proved insufficient to classify ADRs.[9]
Other types of adverse drug reactions are Type C, Type D, Type E, and Type F.[10] Type C was categorized for chronic adverse drug reactions, Type D for delayed adverse drug reactions, Type E for withdrawal adverse drug reactions, and Type F for failure of therapy as an adverse drug reaction. Adverse drug reactions can also be categorized using time-relatedness, dose-relatedness, and susceptibility, which collectively are called the DoTS classification.[10]
Seriousness
The U.S Food and Drug Administration defines a serious adverse event as one when the patient outcome is one of the following:[11]
- Death
- Life-threatening
- Hospitalization (initial or prolonged)
- Disability - significant, persistent, or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities or quality of life.
- Congenital abnormality
- Requires intervention to prevent permanent impairment or damage
Severity is a measure of the intensity of the adverse event in question.[12] The terms "severe" and "serious", when applied to adverse events, are technically very different.[12] They are easily confused but can not be used interchangeably, requiring care in usage.[12] Seriousness usually indicates patient outcome (such as negative outcomes including disability, long-term effects, and death).[12]
A headache is severe if it causes intense pain. There are scales like "visual analog scale" that help clinicians assess the severity. On the other hand, a headache is not usually serious (but may be in case of
In adverse drug reactions, the seriousness of the reaction is important for reporting.[12]
Location
For instance, some
Mechanisms
As research better explains the biochemistry of drug use, fewer ADRs are Type B and more are Type A. Common mechanisms are:
- Abnormal pharmacokinetics due to:
- Synergisticeffects between either:
- a drug and a disease
- two drugs
- Antagonism effects between either:
- a drug and a disease
- two drugs
Abnormal pharmacokinetics
Comorbid disease states
Various diseases, especially those that cause
The Medication Appropriateness Tool for Comorbid Health Conditions in Dementia
Genetic factors
Pharmacogenomics includes how genes can predict potential adverse drug reactions.[17] However, pharmacogenomics is not limited to adverse events (of any type), but also looks at how genes may impact other responses to medications, such as low/no effect or expected/normal responses (especially based on drug metabolism).[17]
Abnormal drug metabolism may be due to inherited factors of either Phase I oxidation or Phase II conjugation.[18][19]
Phase I reactions
Phase I reactions include metabolism by cytochrome P450.[20] Patients have abnormal metabolism by cytochrome P450 due to either inheriting abnormal alleles or due to drug interactions. Tables are available to check for drug interactions due to P450 interactions.[21][22]
Inheriting abnormal
Phase II reactions
Inheriting abnormal N-acetyltransferase which conjugated some drugs to facilitate excretion may affect the metabolism of drugs such as isoniazid, hydralazine, and procainamide.[22][23]
Inheriting abnormal thiopurine S-methyltransferase may affect the metabolism of the thiopurine drugs mercaptopurine and azathioprine.[22]
Protein binding
Protein binding interactions are usually transient and mild until a new steady state is achieved.[24][25] These are mainly for drugs without much first-pass liver metabolism. The principal plasma proteins for drug binding are:[26]
- albumin
- α1-acid glycoprotein
- lipoproteins
Some drug interactions with warfarin are due to changes in protein binding.[26]
Drug interactions
The risk of drug interactions is increased with polypharmacy, especially in older adults.[27]
Additive drug effects
Two or more drugs that contribute to the same mechanism in the body can have additive
Altered metabolism
Some medications can either
Assessing causality
Causality assessment is used to determine the likelihood that a drug caused a suspected ADR.[3] There are a number of different methods used to judge causation, including the Naranjo algorithm, the Venulet algorithm and the WHO causality term assessment criteria. Each have pros and cons associated with their use and most require some level of expert judgement to apply.[31] An ADR should not be labeled as 'certain' unless the ADR abates with a
Assigning causality to a specific agent often proves difficult, unless the event is found during a clinical study or large databases are used. Both methods have difficulties and can be fraught with error. Even in clinical studies, some ADRs may be missed as large numbers of test individuals are required to find a specific adverse drug reaction, especially for rare ADRs. Psychiatric ADRs are often missed as they are grouped together in the questionnaires used to assess the population.[32][33]
Monitoring bodies
Many countries have official bodies that monitor drug safety and reactions. On an international level, the
Epidemiology
A study by the Agency for Healthcare Research and Quality (AHRQ) found that in 2011, sedatives and hypnotics were a leading source for adverse drug events seen in the hospital setting. Approximately 2.8% of all ADEs present on admission and 4.4% of ADEs that originated during a hospital stay were caused by a sedative or hypnotic drug.[41] A second study by AHRQ found that in 2011, the most common specifically identified causes of adverse drug events that originated during hospital stays in the U.S. were steroids, antibiotics, opiates/narcotics, and anticoagulants. Patients treated in urban teaching hospitals had higher rates of ADEs involving antibiotics and opiates/narcotics compared to those treated in urban nonteaching hospitals. Those treated in private, nonprofit hospitals had higher rates of most ADE causes compared to patients treated in public or private, for-profit hospitals.[42]
Medication related harm (MRH) is common after hospital discharge in older adults, but methodological inconsistencies between studies and a paucity of data on risk factors limits clear understanding of the epidemiology. There was a wide range in incidence, from 0.4% to 51.2% of participants, and 35% to 59% of harm was preventable. Medication related harm incidence within 30 days after discharge ranged from 167 to 500 events per 1,000 individuals discharged (17–51% of individuals).[43]
In the U.S., females had a higher rate of ADEs involving opiates and narcotics than males in 2011, while male patients had a higher rate of anticoagulant ADEs. Nearly 8 in 1,000 adults aged 65 years or older experienced one of the four most common ADEs (steroids, antibiotics, opiates/narcotics, and anticoagulants) during hospitalization.[42] A study showed that 48% of patients had an adverse drug reaction to at least one drug, and pharmacist involvement helps to pick up adverse drug reactions.[44]
In 2012, McKinsey & Company concluded that the cost of the 50-100 million preventable error-related adverse drug events would be between US$18–115 billion.[45]
An article published in The Journal of the American Medical Association (JAMA) in 2016 reported adverse drug event statistics from emergency departments around the United States in 2013-2014.[46] From this article, an estimated prevalence of adverse drug events that were presented to the emergency department (ED) was 4 events out of every 1000 people.[46] This article reported that 57.1% of these adverse drug events presented to the ED were in females.[46] As well, out of all of the adverse drug events presented to the emergency department documented in this article, 17.6% were from anticoagulants, 16.1% were from antibiotics, and 13.3% from diabetic agents.[46]
See also
- Alleged problems in the drug approval process
- Classification of Pharmaco-Therapeutic Referrals
- Drug therapy problems
- EudraVigilance (European Union)
- History of pharmacy
- Iatrogenesis
- Lethal dose
- List of withdrawn drugs
- Paradoxical reaction
- Polypharmacy
- Toxicity
- Toxicology
- The Medical Letter on Drugs and Therapeutics
- Yellow Card Scheme (UK)
References
- ^ International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 10 June 1996. Retrieved 16 April 2022.
- ^ "Adverse Drug Reaction (Code C142385)". Enterprise Vocabulary Services. National Cancer Institute. 28 May 2019. Retrieved 27 October 2023.
- ^ S2CID 32296353.
- ^ a b "Why You Need to Take Your Medications as Prescribed or Instructed". Food and Drug Administration. 16 February 2016. Retrieved 27 October 2023.
- ^ PMID 27697815.
- ISBN 978-0-340-90046-8.
- PMID 27842776.
- ^ Rawlins MD, Thompson JW (1977). "Pathogenesis of adverse drug reactions.". In Davies DM (ed.). Textbook of adverse drug reactions. Oxford: Oxford University Press. p. 10.
- ^ Aronson JK (2002). "Drug therapy". In Haslett C, Chilvers ER, Boon NA, Colledge NR, Hunter JA (eds.). Davidson's principles and practice of medicine (19th ed.). Edinburgh: Elsevier Science. pp. 147–163.
- ^ PMID 14630763.
- ^ "What is a Serious Adverse Event?". U.S. Food & Drug Administration. 1 February 2016. Retrieved 17 April 2023.
- ^ a b c d e "ICH E2A Clinical safety data management: definitions and standards for expedited reporting - Scientific guideline" (PDF). European Medicines Agency. 1 June 1995. Retrieved 30 April 2023.
- ISBN 978-0-443-07145-4. Page 146
- ^ "Clinical Drug Use". Archived from the original on 1 November 2007. Retrieved 18 September 2007.
- ^ "MATCH-D Medication Appropriateness Tool for Comorbid Health conditions during Dementia". www.match-d.com.au. Retrieved 1 June 2019.
- PMID 27527376.
- ^ OCLC 1323328254.
- PMID 11710893.
- PMID 12571264.
- PMID 33111191.
- ^ Flockhart DA, Thacker D, McDonald C, Desta Z (2021). "The Flockhart Cytochrome P450 Drug-Drug Interaction Table". Division of Clinical Pharmacology. Indiana University School of Medicine. Archived from the original on 27 March 2023. Retrieved 1 May 2023.
- ^ PMID 12571261.
- ^ PMID 12571262.
- PMID 12473961.
- ^ S2CID 20855578. Archived from the originalon 7 September 2008. Retrieved 18 September 2007.
- PMID 28779826.
- ^ "Drug-Induced Prolongation of the QT Interval and Torsades de Pointes". Lexicomp. 29 April 2023. Retrieved 2 May 2023.
- ^ ISBN 978-1-259-85961-8.
- ^ PMID 35622425.
- S2CID 37301370. Archived from the originalon 1 July 2012. Retrieved 2 June 2011.
- PMID 20852483.
- PMID 14626141.
- ^ Uppsala Monitoring Centre. "The WHO Programme for International Drug Monitoring". who-umc.org. Retrieved 17 April 2023.
- ^ "Pharmacovigilance: post-authorisation". European Medicines Agency. 17 September 2018. Retrieved 17 April 2023.
- ^ a b c "Questions and Answers on FDA's Adverse Event Reporting System (FAERS)". U.S. Food & Drug Administration. 4 June 2018. Retrieved 16 April 2023.
- ^ a b "Canada Vigilance Program". Government of Canada. 24 January 2008. Retrieved 16 April 2023.
- ^ "How we regulate medicines". Australian Government Department of Health and Aged Care Therapeutic Goods Administration. 20 June 2019. Retrieved 2 May 2023.
- ^ "Yellow Card Scheme looks to the future at 50th anniversary forum". GOV.UK. Retrieved 30 April 2023.
- ^ "Information | Making medicines and medical devices safer". yellowcard.mhra.gov.uk. Retrieved 30 April 2023.
- PMID 24228291.
- ^ a b Weiss AJ, Elixhauser A (October 2013). "Characteristics of Adverse Drug Events Originating During the Hospital Stay, 2011" (HCUP Statistical Brief #164). Rockville, MD: Agency for Healthcare Research and Quality. Archived from the original on 24 December 2016. Retrieved 11 November 2013.
- S2CID 49678401.
- PMID 26412813.
- ^ Ebel T, George K, Larsen E, Neal E, Shah K, Shi D (October 2012). "Strength in unity:The promise of global standards in healthcare" (PDF). gs1.org. McKinsey & Company. Archived (PDF) from the original on 19 June 2022. Retrieved 28 October 2022.
- ^ PMID 27893129.
Further reading
- Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy PMC 3312730
External links